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The purpose of the workshop was to identify still obscure or novel
cellular components of the lung, to determine cell function in lung
development and in health that impacts on disease, and to decide
promising avenues for future research to extract and phenotype
these cells. Since robust technologies are now available to identify,
sort, purify, culture, and phenotype cells, progress is now within
sight to unravel the origins and functional capabilities of lung cells in
developmental stages and in disease. The Workshop’s agenda was
to first discuss the lung’s embryologic development, including pro-
genitor and stem cells, and then assess the functional and structural
cells in three main compartments of the lung: (1) airway cells in
bronchial and bronchiolar epithelium and bronchial glands (basal,
secretory, ciliated, Clara, and neuroendocrine cells); (2) alveolar unit
cells (Type 1 cells, Type 2 cells, and fibroblasts in the interstitium);
and (3) pulmonary vascular cells (endothelial cells from different
vascular structures, smooth muscle cells, and adventitial fibro-
blasts). The main recommendations were to: (1) characterize with
better cell markers, both surface and nonsurface, the various cells
within the lung, including progenitor cells and stem cells; (2) obtain
more knowledge about gene expression in specific cell types in
health and disease, which will provide insights into biological and
pathologic processes; (3) develop more methodologies for cell
culture, isolation, sorting, co-culture, and immortalization; and (4)
promote tissue banks to facilitate the procurement of tissue from
normal and from diseased lung for analysis at all levels.
Keywords: novel cells; cell markers; culture methods; progenitor or
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Cellular activity within the structure of viable tissue permits
physiologic functioning of mammalian organ systems that are
incredibly complex, responsive, interactive, and adaptable; col-
lectively, multiple systems support a complex organism’s life. The
respiratory tract, from the point of air entry at the nares and/or
mouth, conditions and moves ambient air down conducting
airways to alveolar units for oxygen–CO2 exchange. To accom-
plish successful respiration, the respiratory tract uses approxi-
mately 40 different resident cell types (Table 1) and their
products to make this occur. Unquestionably, much is known
about normal respiratory function, and what goes awry when
disease develops, thanks to investigative pulmonary research to
date. But the current era of nanotechnology, genomic and other
‘‘-omic’’ approaches favors continued and auspicious research
success in this field.
Yet what still remains unknown in biological science is
humbling. To dramatize this, the July 1, 2005 issue of Science
(1), its 125th anniversary of publication, dedicated a special sec-
tion to the question, ‘‘what don’t we know?’’, exploring 125 ques-
tions that pointed to gaps in our basic scientific knowledge. This
stimulated reflection. While a lot is known about the 40 resident
cell types that compose the human respiratory tract, including
more information about some functions than others, should an
assessment be made to determine if there are cells that are still
not recognized, remain obscure, or may have a limited lifespan or
function during the spectrum of the lung’s ‘‘life’’: from embryonic
beginning to maturation to healthy adult function to aging?
Using the current technologies and ‘‘-omic’’ methods, investigators
might be challenged to study these as yet still obscure cells to
isolate them, determine biomarkers to conclusively identify them,
seek their function and biologic products, and track their origins.
Finally, how might they contribute to normal lung development
and then to lung disease? This desire to learn more about the
ingredients of the respiratory tract is compatible with the recently
formulated NHLBI Strategic Plan: Shaping the Future of Re-
search (2, 3), that is designed to be a ‘‘working blueprint for our
scientific directions over the next 5 to 10 years.’’ A challenge
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outlined is to ‘‘develop a detailed understanding of the molecular,
cellular, and physiological mechanisms that maintain health from
embryonic development to the end of the human lifespan.’’
Who better to point out what they see in lung tissue, wonder
where an influx of cells originates, or what influences cellular
changes (metaplasia) that occur in disease than a group of
clinical and research lung pathologists? So a small group was
invited to be an organizing team for a Workshop that was held
on July 9 and 10, 2007 in Bethesda, Maryland by the Division of
Lung Diseases, National Heart, Lung, and Blood Institute, of
the National Institutes of Health.
Current knowledge of resident lung cells has been largely
established through light and electron microscopy, but meth-
odologic advances in the past 2 to 3 decades have allowed for
refinement of characterization of lung cells, and these methods
should provide a pathway to investigate novel cell lines. Thus,
the overarching concept driving the organization of this Work-
shop was to learn more about common/known cells, as well as
identify novel and still obscure cells in the human lung that may
be important in lung development, homeostasis, injury, repair,
and disease utilizing the most promising new technologies to
create a ‘‘molecular toolbox’’ for isolating, phenotyping, and
discerning the functions of all lung cells.
The primary goals of the workshop were to:
1. Determine cell function of known cells in health and its
impact on disease
2. Identify novel cellular or still obscure components of the
lung
3. Suggest the most promising avenues for future research to
extract and phenotype known and novel cells.
After a pathologist’s perspective of why better characteriza-
tion of resident lung cells would provide better understanding of
normal lung structure and alterations in disease, major segments
of the respiratory tract were explored. The Workshop’s outline
was fashioned to discuss first the lung’s embryonic development,
including airway and vascular development, and then three major
sites and structural tissues within lung: (1) airway cells in
bronchial and bronchiolar mucosa and epithelium (basal, secre-
tory, ciliated, and neuroendocrine cells); (2) alveolar unit cells,
including Type 1 cells, Type 2 cells, and fibroblasts in the
interstitium; and (3) pulmonary vascular cells (endothelial cells
from different size vascular structures, smooth muscle cells, and
adventitial fibroblasts). In addition, the possible lung site and
activity of progenitor and/or stem cells were discussed, as well as
the potential contribution of the bone marrow to supply such cells
in the circulation.
Obviously, many well-known cells and their functions could
not be considered with a constraint on the amount of material to
cover. As a considerable amount is known about many cells that
participate in host defense and innate/adaptive immunity, in-
cluding alveolar macrophages, dendritic cells, lymphocytes, and
inflammatory cells, these cells were not discussed. Many products
made by cells that affect inflammation and fibrosis have recently
been reviewed (4, 5) and were not emphasized, nor were special
respiratory diseases receiving active research discussed specifi-
cally (6, 7). Pulmonary brush cells were the subject of a recent
workshop summary (8).
WHAT IS THE POTENTIAL CLINICAL AND DIAGNOSTIC
IMPACT OF BETTER CHARACTERIZATION OF RESIDENT
AND NOVEL CELLS IN PULMONARY DISEASE?
(A PATHOLOGIST PERSPECTIVE)
As mentioned, the lung is composed of over 40 types of cells
including cells of the epithelium, interstitial connective tissue,
blood vessels, hematopoietic and lymphoid tissue, and the
pleura (9, 10). These are summarized in Table 1. In addition,
some poorly defined cells still exist.







Intermediate (or parabasal) cells
Serous cell (like Clara cells)—major secretory cell in rat. Also present
in human fetal conducting airway mucosa; some reports in adult humans
Brush cell
Special type cells with numerous intracytoplasmic membrane-bound
inclusions
Oncocytes
Nonciliated columnar cells—unclassifiable columnar cells
Metaplastic cells—squamous cells and Clara-mucous cells, bronchiolar
metaplasia
Alveolar cells
Type 1 and type 2 pneumocytes
Transition between 1 and 2 consisting of cuboidal nonciliated cells









Meningothelioid cells of minute meningothelioid nodules
Adipose tissue
Neural cells (intrapulmonary nerves)
Blood vessels
Arteries/veins








Hematopoietic and lymphoid tissue
Lymphocytes
Plasma cells















Perivascular epithelioid cells (PEC)—precursor for LAM cells
Pluripotent epithelial stem cell—precursor for lung cancer—especially small
cell carcinoma—where no precursor is yet identified
Meningothelioid cells
Endothelial progenitor cells
Mucinous cells in certain pediatric conditions
764 PROCEEDINGS OF THE AMERICAN THORACIC SOCIETY VOL 5 2008
 
Resident lung cells are involved with pathologic conditions
in a variety of ways.
1. There are single types of cells linked to specific lung
diseases. For example, glandular cells of the lung give rise
to lung adenocarcinomas (11). Sixty to eighty percent of
lung adenocarcinomas express thyroid transcription factor-
1 (TTF-1), making it a valuable marker (12, 13). Langer-
hans’ cell histiocytosis also represents a pulmonary disor-
der caused by a specific cell, the Langerhans’ cell (14).
2. There are cells that lead to certain differential diagnoses
such as granulomas that raise the consideration of sarcoid-
osis, infection, or Wegener’s granulomatosis (10). Eosino-
phils are another example, and their accumulation in the
lung forming the lesion of eosinophilic pneumonia raises
the consideration of infection, drug toxicity, collagen
vascular disease, allergic bronchopulmonary fungal dis-
ease, Churg-Strauss syndrome, and hypereosinophilic syn-
drome.
3. There are some disorders in which morphologic cellular
changes may not be visible but lung findings reflect local
or systemic cell dysregulation, resulting in accumulation
of material such as amyloid, lipids from storage disorders,
or alveolar proteinosis (10).
4. There are a few disorders in which specific poorly
characterized lung cells appear to be involved. In lym-
phangioleiomyomatosis (LAM), ‘‘perivascular epithelioid
cells (PECs)’’ have been postulated to be the cell of origin
(15); however, these have never been identified in the
lung. Minute meningothelioid nodules are a common
incidental histologic finding in lung biopsies (16, 17).
The function of the cells forming the nodules has not
been determined. However, as these lesions are so
commonly encountered in lung tissue, this suggests that
these cells may play some as yet undiscovered physiologic
role in the lung biology.
5. Most commonly multiple resident cells participate in lung
disease, particularly in inflammatory conditions in chronic
bronchitis, emphysema, asthma, and cystic fibrosis. For
example, desquamative interstitial pneumonia is defined by
a massive increase in airspace macrophages, although
a metaplastic proliferation of type 2 cells lining the alveoli
and a mild proliferation of mesenchymal cells within the
alveolar walls are also present (10). Pathologic diagnoses
for inflammatory diseases of the lung frequently hinge on
patterns of lung reaction that involve multiple cell types,
and the factors that mediate these changes and govern their
proportions are important in understanding basic disease
processes.
Many inflammatory conditions in the lung result in meta-
plasia. Bronchiolar metaplasia refers to the presence of bron-
chiolar type epithelium where it is not normally found, for
example, the abnormal honeycomb spaces in scarred lung
and scarring of bronchioles accompanied by peribronchiolar
metaplasia involving the peribronchiolar alveoli (10, 18). Un-
derstanding why bronchiolar metaplasia occurs in these
regions (as opposed to type 2 cell metaplasia or squamous
metaplasia) is important in understanding the pathogenesis of
these changes.
Squamous metaplasia of the large airways is well known and
considered part of the metaplasia, dysplasia, carcinoma se-
quence in the bronchi (19). Squamous metaplasia also occurs
around small airways in resolving acute lung injury (20), and it
is not known whether this reaction has similar implications for
carcinoma in the large airways. Anecdotal experience would
suggest that it does not.
Type 2 cell hyperplasia refers to lining of airspaces by type 2
cells as opposed to type 1 cells, which normally involve alveoli
(9). It is generally thought that this represents a repair
phenomenon, and pathologically type 2 cell hyperplasia is
used as a common nonspecific marker for injury of the alveolar
type 1 cells. The precise characterization of the events inciting
type 2 cell hyperplasia as well as the factors that govern the
return of type 1 cells lining alveoli during the healing process
have important implications in terms of lung function and
repair after injury.
Thus, better characterization of resident and novel cells in
the lung parenchyma will provide pathologists with a better
understanding of the pathologic conditions of the lung and the
cells involved, as well as provide insight into the pathogenesis
of these conditions based on known functions and interactions
of the cells involved. Characterization of the various forms of
metaplasia in the lung represents a logical extension of study
related to normal resident cells in the lung. It is possible that
certain forms of metaplasia have prognostic significance. For
example, squamous metaplasia in acute lung injury is likely
a reversible change, whereas anecdotal experience suggests
that bronchiolar metaplasia in scarred lung is irreversible.
FURTHER DISCUSSION
As mentioned, the Workshop participants considered four major
topics, beginning with the embryonic and developmental aspects
of the respiratory tract that establish the cell lineages and initial
structures. But in this discussion, a pertinent theme was stressed
that in later life, in later stages of disease, or during injury repair of
the lung, there may be changes in gene expression and cell behavior
that can be reminiscent of those described in some of the specific
developmental processes in the lung. Thus, some of the devel-
opmental signals and cell constituents persisting from the embry-
onic stage, perhaps as progenitor cells, might be reactivated later
during lung repair and regeneration after injury or compensating
for disease processes.
Discussion followed about three structural regions in the lung:
the airway epithelium and submucosal structures, the alveolar
unit, and the pulmonary vasculature. Emphasis was given to the
various major cell lineages and their function (s) in the mature
lung in both normal and disease states. Material is presented
about these topics in accompanying workshop reports, with
recommendations for future research concerning what still needs
to be learned and discovered about lung cells and their functions.
Hopefully, this will help to elucidate further the complexity of the
mature lung, what goes awry in disease, and how research can lead
to better therapies for respiratory illnesses.
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